Conference Menu

Current Event 

Overview
Register
Day 1
Day 2
Day 3
PDF Download
Short Course
Delegate List
Posters
Hotel & Travel
Sponsor & Exhibits
Press Pass 
Request Brochure 
Archives 

Corporate Sponsors

 

 

 

 

 

 

Corporate Support Sponsors

 

Official Publication

 

Lead Sponsoring Publications

 

 

 

 

Sponsoring Publications

 

 

Sponsoring Society

 

Media Partners

 

 

Web Partners

 

 

 

 

 

 

Therapeutic Target Space:
Methods for Druggability Assessment 

Final Days to Register!

Cambridge Healthtech Institute’s Eleventh Annual Structure-Based Drug Design conference brings to focus the latest development in computational technology for drug discovery, and puts structure-based molecular approaches into the perspective of targeted therapeutics.

Conference Highlights: 

• Protein Flexibility
• Fully Synthetic Protein-Protein Interaction Inhibitor
• Fragment-to-Lead Optimization
• High Performance Computing and Collaborative Drug Design
• State-of-the-Art Molecular Dynamics Simulations

 

Keynote Speaker: 

Millisecond-Long Molecular Dynamics Simulations of Proteins on a Special-Purpose Machine

David E. Shaw, Ph.D., Chief Scientist, D. E. Shaw Research

David E. Shaw serves as chief scientist of D. E. Shaw Research and as a senior research fellow at the Center for Computational Biology and Bioinformatics at Columbia University. He received his Ph.D. from Stanford University in 1980, served on the faculty of the Computer Science Department at Columbia until 1986, and founded the D. E. Shaw group in 1988. Since 2001, Dr. Shaw has devoted most of his time to hands-on research in the field of computational biochemistry. His lab is currently involved in the development of new algorithms and machine architectures for high-speed molecular dynamics simulations of biological macromolecules, and in the application of such simulations to basic scientific research and computer-assisted drug design.

Dr. Shaw was appointed to the President’s Council of Advisors on Science and Technology by President Clinton in 1994, and again by President Obama in 2009. He is a fellow of the American Academy of Arts and Sciences and of the American Association for the Advancement of Science.

Anton: Molecular Dynamics Simulation for Drug Design 

 

 

Dinner Short Course: 

June 8, 2011

 

Identification of Druggable Sites for Protein-Protein Interaction Targets 

 

Scientific Advisory Board:  José Duca, Ph.D., Head, Computer Aided Drug Discovery, Novartis  Alan C. Rigby, Ph.D., Vice President, Research, Computational Discovery, ImClone Systems-A wholly-owned subsidiary of Eli Lilly and Company  Tomi Sawyer, Ph.D., CSO, Aileron Therapeutics, Inc.; Editor-in-Chief, Chemical Biology & Drug Design  Woody Sherman, Ph.D., Vice President, Applications Science, Schrödinger, Inc.  Gergely Toth, Ph.D., Research Fellow, Department of Chemistry, University of Cambridge  Marcel Verdonk, Ph.D., Director, Computational Chemistry and Informatics, Astex Therapeutics Ltd.  Pat Walters, Ph.D., Senior Research Fellow, Vertex Pharmaceuticals, Inc.  Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group

 

Co-Located With:
Next-Gen Kinase Inhibitors